Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Bayer346 enrolled

Overview

In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line treatment). Additionally the researchers are also interested in the occurrence of bone fractures and other skeletal events. Basis for this study will be the US based Flatiron database which provides access to clinical data for cancer patients.

Study Type

OBSERVATIONAL

Enrollment

346

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

Radium-223 (Xofigo, BAY88-8223)DRUG

Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with documented mCRPC receiving 1L NAHs. * Initiation of Ra-223 after 1L NAH therapy, or * Initiation of sequential NAH therapy after 1L NAH therapy Exclusion criteria: * Patients involved in clinical trials * Patients who received combined therapies in 1L or 2L

Outcomes

Primary Outcomes

Overall survival (OS) from initiation of 2L therapy of Radium-223 in patients with mCRPC after 1L NAH therapy